Last reviewed · How we verify
NCT02875262: DASH
Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial
Phase 1, PHASE2 trial testing Deferoxamine in Intracranial Aneurysm in 40 participants. Status unknown.
1 January 2024
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 2 December 2022 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 2 locations across Netherlands |
Drugs / interventions tested
- Deferoxamine (DEFEROXAMINE) — full drug profile →
- placebo
Conditions studied
- Intracranial Aneurysm — all drugs for Intracranial Aneurysm →
- Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
Sponsor
Radboud University Medical Center
Who can join
Adults 18 to 85, any sex, with Intracranial Aneurysm or Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aneurysmal subarachnoid hemorrhage (SAH) is a form of stroke in which secondary neurological deterioration is an important cause of mortality and morbidity. These secondary changes, so called delayed cerebral ischemia (DCI), are caused by lysis of erythrocytes which can react to form iron, an toxic substance to the brain. Iron chelators remove the excess of iron and are standard care in iron-overloaded patients. Deferoxamine (DFO) an chelator has not been evaluated in SAH patients. This study evaluates the safety of deferoxamine in SAH patients.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Intracerebral Iron Accumulation may be Associated with Secondary Brain Injury in Patients with Poor Grade Subarachnoid Hemorrhage.
Helbok R, Rass V, Kofler M, Talasz H, et al · · 2022 · cited 23× · PMID 34374002 · DOI 10.1007/s12028-021-01278-1 -
Iron chelators for acute stroke.
Van der Loo LE, Aquarius R, Teernstra O, Klijn K, et al · · 2020 · cited 10× · PMID 33236783 · DOI 10.1002/14651858.cd009280.pub3 -
Beyond the bleed: complications after aneurysmal subarachnoid hemorrhage. Pathophysiology, clinical implications, and management strategies: a review.
Busl KM, Bogossian EG, Claassen J, Helbok R, et al · · 2025 · cited 4× · PMID 41029753 · DOI 10.1186/s13054-025-05640-z -
Iron Hemostasis in Patients With Subarachnoid Hemorrhage and the Role of Early CSF Drainage.
Bi T, Koch H, Kremer B, Höllig A. · · 2025 · cited 2× · PMID 40489716 · DOI 10.1212/wnl.0000000000213767 -
Heme as an inducer of cerebral damage in hemorrhagic stroke: potential therapeutic implications.
Vasconcellos LRDC, Pimentel-Coelho PM. · · 2022 · cited 2× · PMID 35142675 · DOI 10.4103/1673-5374.335148
Verify or expand the search:
- PubMed search for NCT02875262
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Deferoxamine
Trials testing the same drug.
- NCT07162363 — Synergistic Minimally Invasive Surgery and Deferoxamine in ICH · Phase 2, PHASE3 · not yet recruiting
- NCT07023666 — Early Screening and Treatment of Heart Complication in Sickle Cell Disease · Phase 2 · recruiting
- NCT05748587 — Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke · completed
- NCT03137966 — Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers · Phase 2 · not yet recruiting
- NCT04633889 — Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury · Phase 2 · active not recruiting
Other recruiting trials for Intracranial Aneurysm
Currently open trials in the same condition.
- NCT07123818 — AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening · NA · active not recruiting
- NCT06494436 — Microvention AnEurysm & STroke Real-life Data cOllection · recruiting
- NCT06588543 — Patient-specific Planning of Minimally Invasive Brain Interventions Based on Vascular-hemodynamic Mapping · recruiting
- NCT05831202 — SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial · Phase 3 · active not recruiting
- NCT06416657 — General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Usin · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02875262 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 24 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02875262.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing